In the past week, EDIT stock has gone down by -14.20%, with a monthly gain of 41.82% and a quarterly surge of 6.92%. The volatility ratio for the week is 10.99%, and the volatility levels for the last 30 days are 11.35% for Editas Medicine Inc The simple moving average for the past 20 days is -3.67% for EDIT’s stock, with a -43.19% simple moving average for the past 200 days.
Is It Worth Investing in Editas Medicine Inc (NASDAQ: EDIT) Right Now?
EDIT has 36-month beta value of 2.12. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 1 as “overweight,” 9 as “hold,” and 0 as “sell.”
The public float for EDIT is 82.93M, and currently, short sellers hold a 15.27% ratio of that float. The average trading volume of EDIT on May 09, 2025 was 3.73M shares.
EDIT) stock’s latest price update
The stock price of Editas Medicine Inc (NASDAQ: EDIT) has surged by 4.51 when compared to previous closing price of 1.33, but the company has seen a -14.20% decline in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-05 that CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) — Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that it plans to announce Q1 2025 financial results and business updates on May 12 via press release and SEC filings. As previously announced, the Company does not plan to host quarterly financial results conference calls moving forward.
Analysts’ Opinion of EDIT
Many brokerage firms have already submitted their reports for EDIT stocks, with H.C. Wainwright repeating the rating for EDIT by listing it as a “Buy.” The predicted price for EDIT in the upcoming period, according to H.C. Wainwright is $3 based on the research report published on April 28, 2025 of the current year 2025.
EDIT Trading at -2.27% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -79.22% of loss for the given period.
Volatility was left at 11.35%, however, over the last 30 days, the volatility rate increased by 10.99%, as shares surge +20.87% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -24.46% lower at present.
During the last 5 trading sessions, EDIT fell by -14.20%, which changed the moving average for the period of 200-days by -73.32% in comparison to the 20-day moving average, which settled at $1.4430. In addition, Editas Medicine Inc saw 9.45% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Lucera Erick, who sale 4,109 shares at the price of $1.71 back on Mar 04 ’25. After this action, Lucera Erick now owns 112,720 shares of Editas Medicine Inc, valued at $7,030 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 16,632 shares at $1.71 during a trade that took place back on Mar 04 ’25, which means that O’Neill Gilmore Neil is holding 295,474 shares at $28,452 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -7.77 for the present operating margin
- 0.82 for the gross margin
The net margin for Editas Medicine Inc stands at -7.34. The total capital return value is set at -0.95. Equity return is now at value -98.10, with -56.40 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -6.0.
Currently, EBITDA for the company is -231.28 million with net debt to EBITDA at 0.42. When we switch over and look at the enterprise to sales, we see a ratio of 0.61. The receivables turnover for the company is 1.99for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.75.
Conclusion
To put it simply, Editas Medicine Inc (EDIT) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
